Clinical Trial Update: A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms [Phase 1]

View source ↗

Summary

Phase 1 trial update showing SHR2554 is being studied in relapsed or refractory mature lymphoid neoplasms; the study (NCT03603951) is active but not recruiting,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory Mature Lymphoid Neoplasms

Drugs mentioned

• SHR2554

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Relapsed or Refractory Mature Lymphoid Neoplasms | Phase 1 | Status: ACTIVE_NOT_RECRUITING